Repligen falls on downbeat annual results forecast

Repligen

21/02/2024 14:11

** Shares of Repligen  RGEN.O , which makes products for
biopharma companies, fall 6.9% to $186 premarket
    ** Co forecasts FY24 revenue between $620 mln and $650 mln;
below Wall Street view of $660.7 mln - LSEG data  
    ** Co sees FY24 adj. profit in the range of $1.42 - $1.49
per share; missing analyst estimate of $1.77
    ** Q4 revenue fell to $155.7 mln from $186.8mln a year
earlier
    ** Repligen posts Q4 loss of $25.5 mln; compared with a
profit of $48.7 mln a year earlier 
    ** Ten of 13 brokerages rate the stock "buy" or higher,
three "hold"; their median PT is $192.50
    ** In 2023, RGEN shares advanced 6.2% 

 (Reporting by Khushi Singh in Bengaluru)
 ((Khushi.Singh@thomsonreuters.com;))